Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029043 | 0.81 | RAB9A (0.54) | AOC3LMNA | |
| SCHEMBL27006320 | 0.75 | AOC3 (0.47) | TDP1HPGDAOC3LMNASMN1; SMN2 | |
| SCHEMBL27130324 | 0.75 | AOC3 (0.47) | TDP1HPGDAOC3LMNASMN1; SMN2 | |
| SCHEMBL14316409 | 0.72 | KMT2A (0.50) | AKT1SLC6A2SLC6A4SLC6A3HPGD | |
| Oxalic Acid SCHEMBL1573558 | 0.72 | MEN1 (0.46) | CNR1TDP1LMNA | |
| SCHEMBL1155443 | 0.69 | AOC3 (0.53) | TDP1HPGDAOC3LMNASMN1; SMN2 | |
| SCHEMBL5437078 | 0.69 | AOC3 (0.53) | TDP1HPGDAOC3LMNASMN1; SMN2 | |
| SCHEMBL4297797 | 0.69 | AOC3 (0.53) | TDP1HPGDAOC3LMNASMN1; SMN2 | |
| SCHEMBL11592029 | 0.68 | RAB9A (0.52) | TDP1HTTAOC3LMNA | |
| SCHEMBL8372487 | 0.68 | MEN1 (0.50) | CNR1LMNAHDAC4HDAC7HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229355-B1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI SA (FR) | 2012-09-19 | — | — | EP | claimed |
| US-8207355-B2 | Method for preparing azetidine derivatives | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | claimed |
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | claimed |
| EP-2229355-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | Sanofi-Aventis (FR) | 2010-09-22 | — | — | EP | claimed |
| WO-2009103883-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | WO | claimed |
| EP-2229355-B1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI SA (FR) | 2012-09-19 | — | — | EP | disclosed |
| US-8207355-B2 | Method for preparing azetidine derivatives | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8207355-B2 | Method for preparing azetidine derivatives | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8207355-B2 | Method for preparing azetidine derivatives | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-2229355-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | Sanofi-Aventis (FR) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009103883-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009103883-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | QDPR, AZI2, NISCH | AKT1 2872/4885CNR1 2397/4885SLC6A2 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.